TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06035614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: exciplex
Description: exciplex, excimer lamp 308nm produced by clarteis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus ointment
Description: tacrolimus monohydrate ointment 0.1% TACRUS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus ointment
Description: tacrolimus monohydrate ointment 0.1% TACRUS
Study: NCT04963361

Intervention type: OTHER
Intervention: patients were exposed to fear of movement
Description: Patients completed the questionnaires independently

Intervention type: OTHER
Intervention: patients were not exposed to fear of movement
Description: Patients completed the questionnaires independently
Study: NCT06032052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single drug chemotherapy plus immunotherapy
Description: The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
Study: NCT04874233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU6
Description: HU6 is active study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU6
Description: HU6 is active study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU6
Description: HU6 is active study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug N = 20
Study: NCT04714437

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A1
Description: The participant will be asked to chew the latex bag changing the side once.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A3
Description: The participant will be asked to chew the latex bag changing the side three times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A3
Description: The participant will be asked to chew the latex bag changing the side three times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A3
Description: The participant will be asked to chew the latex bag changing the side three times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A3
Description: The participant will be asked to chew the latex bag changing the side three times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A3
Description: The participant will be asked to chew the latex bag changing the side three times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A3
Description: The participant will be asked to chew the latex bag changing the side three times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A5
Description: The participant will be asked to chew the latex bag changing the side five times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A5
Description: The participant will be asked to chew the latex bag changing the side five times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A5
Description: The participant will be asked to chew the latex bag changing the side five times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A5
Description: The participant will be asked to chew the latex bag changing the side five times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A5
Description: The participant will be asked to chew the latex bag changing the side five times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A5
Description: The participant will be asked to chew the latex bag changing the side five times.
Study: NCT06474689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR
Description: EMDR is based on the Adaptive Information Process (AIP) model, which posits that the traumatic event experienced by a subject is stored in memory along with the disturbing emotions, perceptions, cognitions, and physical sensations that characterized that moment. All this information is stored in a dysfunctional way within neural networks and unable to connect with other networks with useful information. The information enclosed in the neural networks, not being able to be processed, continue to cause discomfort in the subject, up to the onset of pathologies such as post-traumatic stress disorder (PTSD) and other psychological disorders. The goal of EMDR is to restore the adaptive processing of information in order to achieve the adaptive resolution by creating new and more functional connections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT-E is based on the transdiagnostic theory for eating disorders. According to this theory, there is an overvaluation of shape, weight, eating and their control that people use to judge themselves which represents the core feature of maintaining eating disorder symptoms including binge eating. The goals of CBT-E are to increase the understanding of eating disorders, reduce weight concerns, and establish a pattern of regular eating by addressing the mechanisms that have been maintaining the eating disorder psychopathology including body image disturbances and reactions to life events and emotions. The goals of CBT-OB are to help patients to reach, accept and maintain a healthy weight loss by adopting a healthy lifestyle.
Study: NCT05443425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Therapy
Description: Given steroid therapy
Study: NCT06442540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Agents
Description: Hot pack

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: HVLA manipulation of SI joint

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises
Description: Supine abdominal draw-in Hold 8s 3s off x 2 Abdominal draw-in, with one knee drawn to the chest. Hold 8s 3s off x 2 Abdominal draw-in, with the heels sliding backward one after the other. 10 reps 3s off x 2 Abdominal draw-in, with both knees drawn to the chest. Hold 8s 3s off x 2 Supine twist 15 reps 3s off x 3 Prone bridging on elbows Hold 8s 3s off x 3 Side bridging on elbows Hold 8s 3s off x 3 Quadruped opposite arm-leg lift Hold 8s 3s off x 3 Advance to the stage 2 when the patient can hold 30 reps for an 8-sec hold.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises
Description: Supine abdominal draw-in Hold 8s 3s off x 2 Abdominal draw-in, with one knee drawn to the chest. Hold 8s 3s off x 2 Abdominal draw-in, with the heels sliding backward one after the other. 10 reps 3s off x 2 Abdominal draw-in, with both knees drawn to the chest. Hold 8s 3s off x 2 Supine twist 15 reps 3s off x 3 Prone bridging on elbows Hold 8s 3s off x 3 Side bridging on elbows Hold 8s 3s off x 3 Quadruped opposite arm-leg lift Hold 8s 3s off x 3 Advance to the stage 2 when the patient can hold 30 reps for an 8-sec hold.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramusular electrotherapy
Description: Intramuscular electrotherapy/ 3 sessions per week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue mobility
Description: Stretching and Myofacial Release of piriformis and erector spinae
Study: NCT06451315

Intervention type: PROCEDURE
Intervention: Analyze CTscans pre-operatively by Nurea System
Description: CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by system develop by Nurea

Intervention type: PROCEDURE
Intervention: Analyze CTscans pre-operatively by hospital practitioner
Description: CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by an hospital practitioner
Study: NCT04713787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
Study: NCT06014736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XJ101 for Injection
Description: XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only excipients.
Study: NCT04727476

Intervention type: DRUG
Intervention: Lisdexamfetamine
Description: Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.
Study: NCT04340908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: 10 mg tablet, oral, once daily, 1-year treatment, postoperation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: matching placebo tablet, oral, once daily, 1-year treatment, postoperation
Study: NCT05914025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
Study: NCT04613882

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Toric Custom Made Contact lens
Description: Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Toric Custom Made Contact lens
Description: Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Toric Custom Made Contact lens
Description: Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Spherical Contact Lenses
Description: Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Spherical Contact Lenses
Description: Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Spherical Contact Lenses
Description: Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle Correction
Description: Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
Study: NCT01048983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
Study: NCT04613882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle Correction
Description: Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle Correction
Description: Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
Study: NCT06017674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Pulsed Radiofrequency
Description: A 22-gauge 10 cm radiofrequency cannula with a 10-mm active tip was advanced to the mid-tibiofemoral joint under fluoroscopic guidance. After needle insertion, paresthesia-pain and motor stimulation tests were performed using sensory (50 Hz) and motor (2 Hz, 1 V) stimulation to confirm the absence of stimulation. Intra-articular Pulsed Radiofrequency (IAPRF) was applied at 45 V voltage for 20 ms pulse width for 360 s, followed by a 480 ms silent phase. The tissue temperature was adjusted to not exceed 42°C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Injection
Description: 8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Injection
Description: 8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.
Study: NCT06380634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group- Motivational Interview
Description: Pregnant women who applied to the gynecology clinic and met the inclusion criteria were informed about the study. Those who agreed were informed about the purpose of the research. Firstly, the Informed Volunteer and Introductory Information Form was applied to the women, then the Personal Care Products Use Evaluation Form, Self-Efficacy Scale and Endocrine Disruptors Attitude Scale were applied. Then, the experimental group was informed about the motivational interviewing technique. A total of 3 interviews were held. The final test was made at the fourth meeting.
Study: NCT06379113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: 2.5mg po qd.
Study: NCT04774822

Intervention type: PROCEDURE
Intervention: Color Fundus Photography
Description: Stereoscopic Fundus photography

Intervention type: PROCEDURE
Intervention: Color Fundus Photography
Description: Stereoscopic Fundus photography

Intervention type: DRUG
Intervention: Mydriatics Agent
Description: Eye dilating agent

Intervention type: DRUG
Intervention: Mydriatics Agent
Description: Eye dilating agent

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Tomographic imaging of retina

Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Tomographic imaging of retina
Study: NCT05023967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Metformin Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Use continuous glucose monitoring system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Use continuous glucose monitoring system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Receive nutritional counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-Term Fasting
Description: Perform intermittent fasting
Study: NCT06273982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)
Description: STEP-UP consists of 8 to 12 sessions of behavioral therapy for anxiety and / or depression. Skills taught include relaxation, problem solving, and exposure / behavioral activation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ARC (assisted referral to community care)
Description: ARC consists of referral to community mental health treatment-as-usual. Families are provided psychoeducation about anxiety and depression and the benefits of treatment, lists of local community providers, and a problem-solving discussion about obstacles to obtaining care.
Study: NCT01048983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
Study: NCT06021951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid 180 MG Oral Tablet
Description: Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet
Description: Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]
Study: NCT01048983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
Study: NCT05668936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Participants will receive a subcutaneous injection of cotadutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide-placebo
Description: Participants will receive a subcutaneous injection of cotadutide-placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide-placebo
Description: Participants will receive a subcutaneous injection of cotadutide-placebo.
Study: NCT06111196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection
Description: 100mg/4ml;single dose;intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab injection
Description: 100mg/4ml;single dose;intravenous injection
Study: NCT06217575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alpha neurofeedback training
Description: Alpha neurofeedback training affords the participant the ability to monitor cortical EEG waves and entrain to a specific rhythm using visual feedback. Alpha is measured between 8-12Hz and is associated with cortical inhibition. Aging related changes in alpha have been associated with loss of modulation ability. However, alpha training may afford increased perception of visual details.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Attention Training
Description: Visual attention training involves repeated testing on the location and identity of objects in the visual field. Also called the Dual Decision task training, objects are briefly presented in a radial field of view surrounding a gaze fixation point. The participant is asked to remember the location and object presented within the field. The test progressively increases in difficulty by limiting the amount of time the object is presented on screen. Accuracy is measured by either a correct or incorrect response (binary response).
Study: NCT06570343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl-Morphine
Description: Intrathecal injection of bupivacaine, fentanyl and morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intrathecal injection of bupivacaine and morphine
Study: NCT06086561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Anisotropy Measurement Device
Description: The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
Study: NCT06648538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonix Care
Description: Phonix Care consists of a 5-month digital therapeutic program that encourages the user to engage in non-digital activities through pre-defined screen rules and off-screen challenges validated by smartphone sensors.
Study: NCT06431893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtibatinase
Description: Full Target Dose of pegtibatinase BIW
Study: NCT06064838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoids
Description: 1 capsule every 12h for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavonoids
Description: 1 capsule every 12h for 90 days